Dimitrios Papantoniou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dimitrios Papantoniou has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Eva Tiensuu Janson
Department of Medical Sciences, Endocrine Oncology Uppsala University Uppsala Sweden
4 shared publicationsMalin Grönberg
Department of Medical Sciences, Endocrine Oncology Uppsala University Uppsala Sweden
4 shared publicationsStaffan Welin
Department of Medical Sciences, Endocrine Oncology Uppsala University Uppsala Sweden
3 shared publicationsKalle Landerholm
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
2 shared publicationsLinn Pettersson
Department of Oncology, Ryhov County Hospital, Jönköping, Sweden
2 shared publications- Anders Sundin
Department of Surgical Sciences, Radiology and Molecular Imaging Uppsala University Uppsala Sweden
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (10)
Proteomic profiling identifies candidate biomarkers for small intestinal neuroendocrine tumours G1 and G2
Although small intestinal neuroendocrine tumours (SI‐NET) Grade 1 (G1) and 2 (G2) are often studied together, clinical course and response to treatment may differ. We hypothesized that these tumour groups express different markers in blood that may inform future treatment strategies. Blood from 107 SI‐NET patients (G1 n = 64, G2 n = 43) and 50 healthy controls was analysed with proximity extension assay (Olink, Uppsala, Sweden). Two oncology protein panels were used. Outcomes were analysed with regression analysis and machine learning algorithms (Random Forest, Boruta). In age‐adjusted analyses, 188 proteins differed between patients and healthy controls, with most being elevated in patients. Six proteins were elevated in G2 vs. G1 patients. After adjusting for age, Retbindin (RTBDN), Cryptic family protein 1 (CFC1), and Calbindin 1 (CALB1) remained significant, while adjusting for age and stage left only RTBDN significant. In a stage IV‐restricted analysis, RTBDN was higher in G2 than in G1 (estimate 1.688; 95% CI 0.796–2.580; p <0.001). RTBDN and Midkine (MDK) were associated with poor survival, whereas the opposite was seen for Integrin subunit alpha V (ITGAV). RTBDN emerged as the only candidate biomarker associated with tumour grade after adjustment for age and stage in the G1/G2 analysis. In the stage IV‐restricted analysis, RTBDN remained the top‐ranked protein and showed a similar direction of association without reaching the strict Bonferroni‐adjusted significance threshold. Higher RTBDN levels were also associated with increased mortality risk. These findings are exploratory and require independent validation before clinical application.
- 9 October 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (10)
Open AccessProteomic profiling identifies candidate biomarkers for small intestinal neuroendocrine tumours G1 and G2
Although small intestinal neuroendocrine tumours (SI‐NET) Grade 1 (G1) and 2 (G2) are often studied together, clinical course and response to treatment may differ. We hypothesized that these tumour groups express different markers in blood that may inform future treatment strategies. Blood from 107 SI‐NET patients (G1 n = 64, G2 n = 43) and 50 healthy controls was analysed with proximity extension assay (Olink, Uppsala, Sweden). Two oncology protein panels were used. Outcomes were analysed with regression analysis and machine learning algorithms (Random Forest, Boruta). In age‐adjusted analyses, 188 proteins differed between patients and healthy controls, with most being elevated in patients. Six proteins were elevated in G2 vs. G1 patients. After adjusting for age, Retbindin (RTBDN), Cryptic family protein 1 (CFC1), and Calbindin 1 (CALB1) remained significant, while adjusting for age and stage left only RTBDN significant. In a stage IV‐restricted analysis, RTBDN was higher in G2 than in G1 (estimate 1.688; 95% CI 0.796–2.580; p <0.001). RTBDN and Midkine (MDK) were associated with poor survival, whereas the opposite was seen for Integrin subunit alpha V (ITGAV). RTBDN emerged as the only candidate biomarker associated with tumour grade after adjustment for age and stage in the G1/G2 analysis. In the stage IV‐restricted analysis, RTBDN remained the top‐ranked protein and showed a similar direction of association without reaching the strict Bonferroni‐adjusted significance threshold. Higher RTBDN levels were also associated with increased mortality risk. These findings are exploratory and require independent validation before clinical application.
- Open Access
- 10 May 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (5) , e70188
Phosphohistone H3 and Ki‐67 as prognostic markers in metastatic small intestinal neuroendocrine tumours: A comparative, retrospective cohort study
Ki‐67 index and mitotic count form the basis of grading of small intestinal neuroendocrine tumours (siNET). We hypothesized that the mitosis‐specific marker phosphohistone H3 (PHH3) might better correlate with cancer‐specific survival (CSS) and with response to treatment. We evaluated the association between Ki‐67 index, PHH3‐estimated mitotic count, and survival outcomes in a retrospective cohort of 73 consecutive patients with metastatic siNET. Additionally, we estimated the optimal cut‐off for PHH3 and cross‐validated the outcome. Both markers adequately distinguished CCS when comparing lower and higher proliferation groups (Ki‐67: 128 vs. 95 m; PHH3: 149 vs. 88 m). They were strongly associated with CSS as continuous (HR 1.18 [1.08–1.28] and 1.16 [1.09–1.25]), and dichotomous variables (HR 2.96 [1.31–6.67] and 3.11 [1.50–6.46]). The Cox model based on PHH3 displayed slightly better optimism‐corrected Harrell's c‐index (0.71 vs. 0.68) and Akaike information criterion (219 vs. 223). Additionally, PHH3 showed significant association with PFS after treatment with somatostatin analogues (HR 1.12 [1.03–1.21]), and borderline significant association with PFS after treatment with peptide receptor radionuclide therapy (HR 1.11 [1.00–1.24]). A cut‐off of >2 mitoses per 10 high‐power fields estimated by PHH3 seemed to have better discrimination power compared to the standard WHO cut‐off (2 mitoses per 10 HPF might better distinguish G1 and G2 tumours.
- 10 May 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (5) , e70188
Open AccessPhosphohistone H3 and Ki‐67 as prognostic markers in metastatic small intestinal neuroendocrine tumours: A comparative, retrospective cohort study
Ki‐67 index and mitotic count form the basis of grading of small intestinal neuroendocrine tumours (siNET). We hypothesized that the mitosis‐specific marker phosphohistone H3 (PHH3) might better correlate with cancer‐specific survival (CSS) and with response to treatment. We evaluated the association between Ki‐67 index, PHH3‐estimated mitotic count, and survival outcomes in a retrospective cohort of 73 consecutive patients with metastatic siNET. Additionally, we estimated the optimal cut‐off for PHH3 and cross‐validated the outcome. Both markers adequately distinguished CCS when comparing lower and higher proliferation groups (Ki‐67: 128 vs. 95 m; PHH3: 149 vs. 88 m). They were strongly associated with CSS as continuous (HR 1.18 [1.08–1.28] and 1.16 [1.09–1.25]), and dichotomous variables (HR 2.96 [1.31–6.67] and 3.11 [1.50–6.46]). The Cox model based on PHH3 displayed slightly better optimism‐corrected Harrell's c‐index (0.71 vs. 0.68) and Akaike information criterion (219 vs. 223). Additionally, PHH3 showed significant association with PFS after treatment with somatostatin analogues (HR 1.12 [1.03–1.21]), and borderline significant association with PFS after treatment with peptide receptor radionuclide therapy (HR 1.11 [1.00–1.24]). A cut‐off of >2 mitoses per 10 high‐power fields estimated by PHH3 seemed to have better discrimination power compared to the standard WHO cut‐off (2 mitoses per 10 HPF might better distinguish G1 and G2 tumours.
- Open Access
- 13 March 2024
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (3) , e13379
Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients
Several inflammation scores have shown association with survival outcomes for patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT). However, whether these scores add value to established prognostic factors remains unknown. In this retrospective, cohort study of 557 NET patients undergoing PRRT in a tertiary referral centre from 2005 to 2015, we examined inflammatory markers and scores previously associated with cancer outcomes, using Cox proportional hazard models and Akaike's information criterion. Lower albumin (hazard ratio [95% confidence interval], .91 [.87–.95] per unit), as well as higher C‐reactive protein (CRP; 1.02 [1.01–1.02]), Glasgow Prognostic Score (GPS; 1 vs. 0: 1.67 [1.14–2.44], 2 vs. 0 3.60 [2.24–5.79]), CRP/albumin ratio (1.84 [1.43–2.37]) and platelet count (Plt) × CRP, but not white blood cell, neutrophil and thrombocyte counts or derived neutrophil to lymphocyte ratio (dNLR), were associated with shorter median overall survival (OS) in an adjusted analysis. The addition of parameters based on albumin and CRP, but not dNLR, to a base model including age, chromogranin A, the cell proliferation marker Ki‐67, performance status, tumour site and previous treatments improved the predictive accuracy of the base model. In an exploratory analysis of patients with available erythrocyte sedimentation rate (ESR) and CRP, ESR emerged as the most powerful predictor. When added to a prognostic model for OS in NET patients treated with PRRT, most inflammation scores further improved the model. Albumin was the single marker adding most value to the set of established prognostic markers, whereas dNLR did not seem to improve the model's prognostic ability.
- 13 March 2024
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (3) , e13379
Open AccessHypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients
Several inflammation scores have shown association with survival outcomes for patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT). However, whether these scores add value to established prognostic factors remains unknown. In this retrospective, cohort study of 557 NET patients undergoing PRRT in a tertiary referral centre from 2005 to 2015, we examined inflammatory markers and scores previously associated with cancer outcomes, using Cox proportional hazard models and Akaike's information criterion. Lower albumin (hazard ratio [95% confidence interval], .91 [.87–.95] per unit), as well as higher C‐reactive protein (CRP; 1.02 [1.01–1.02]), Glasgow Prognostic Score (GPS; 1 vs. 0: 1.67 [1.14–2.44], 2 vs. 0 3.60 [2.24–5.79]), CRP/albumin ratio (1.84 [1.43–2.37]) and platelet count (Plt) × CRP, but not white blood cell, neutrophil and thrombocyte counts or derived neutrophil to lymphocyte ratio (dNLR), were associated with shorter median overall survival (OS) in an adjusted analysis. The addition of parameters based on albumin and CRP, but not dNLR, to a base model including age, chromogranin A, the cell proliferation marker Ki‐67, performance status, tumour site and previous treatments improved the predictive accuracy of the base model. In an exploratory analysis of patients with available erythrocyte sedimentation rate (ESR) and CRP, ESR emerged as the most powerful predictor. When added to a prognostic model for OS in NET patients treated with PRRT, most inflammation scores further improved the model. Albumin was the single marker adding most value to the set of established prognostic markers, whereas dNLR did not seem to improve the model's prognostic ability.
- Open Access
- 17 May 2023
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (6) , e438-e448
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
- 17 May 2023
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (6) , e438-e448
Open AccessTreatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
- Open Access
- 4 April 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-10
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge and evidence for late-line treatments in real-life is limited. The present study investigates the efficacy and safety of an oral metronomic chemo-hormonal regimen including cyclophosphamide, etoposide, estramustine, ketoconazole and prednisolone (KEES) administered in a consecutive biweekly schedule. Methods: A retrospective cohort study in two Swedish regions was conducted. Overall (OS) and progression-free survival (PFS), biochemical response rate (bRR) and toxicities were analyzed. Results: One hundred and twenty-three patients treated with KEES after initial treatment with at least a taxane or an androgen-receptor targeting agents (ARTA) were identified. Of those, 95 (77%) had received both agents and were the primary analysis population. Median (95% CI) OS and PFS in the pre-treated population were 12.3 (10.1–15.0) and 4.4 (3.8–5.5) months, respectively. Biochemical response, defined as ≥ 50% prostate-specific antigen (PSA) reduction, occurred in 26 patients (29%), and any PSA reduction in 59 (65%). PFS was independent of prior treatments used, and KEES seemed to be effective in late treatment lines. The bRR was higher compared to historical data of metronomic treatments in docetaxel and ARTA pre-treated populations. In multivariable analyses, performance status (PS) ≥ 2 and increasing alkaline phosphatase (ALP) predicted for worse OS. Nausea, fatigue, thromboembolic events and bone marrow suppression were the predominant toxicities. Conclusions: KEES demonstrated meaningful efficacy in heavily pre-treated CRPC patients, especially those with PS 0–1 and lower baseline ALP, and had an acceptable toxicity profile.
- 4 April 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-10
Open AccessActivity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge and evidence for late-line treatments in real-life is limited. The present study investigates the efficacy and safety of an oral metronomic chemo-hormonal regimen including cyclophosphamide, etoposide, estramustine, ketoconazole and prednisolone (KEES) administered in a consecutive biweekly schedule. Methods: A retrospective cohort study in two Swedish regions was conducted. Overall (OS) and progression-free survival (PFS), biochemical response rate (bRR) and toxicities were analyzed. Results: One hundred and twenty-three patients treated with KEES after initial treatment with at least a taxane or an androgen-receptor targeting agents (ARTA) were identified. Of those, 95 (77%) had received both agents and were the primary analysis population. Median (95% CI) OS and PFS in the pre-treated population were 12.3 (10.1–15.0) and 4.4 (3.8–5.5) months, respectively. Biochemical response, defined as ≥ 50% prostate-specific antigen (PSA) reduction, occurred in 26 patients (29%), and any PSA reduction in 59 (65%). PFS was independent of prior treatments used, and KEES seemed to be effective in late treatment lines. The bRR was higher compared to historical data of metronomic treatments in docetaxel and ARTA pre-treated populations. In multivariable analyses, performance status (PS) ≥ 2 and increasing alkaline phosphatase (ALP) predicted for worse OS. Nausea, fatigue, thromboembolic events and bone marrow suppression were the predominant toxicities. Conclusions: KEES demonstrated meaningful efficacy in heavily pre-treated CRPC patients, especially those with PS 0–1 and lower baseline ALP, and had an acceptable toxicity profile.
- Open Access
- 1 March 2023
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 30 (3)
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
Small intestinal neuroendocrine tumours (Si-NET) are often studied as a uniform group. Proliferation index Ki-67 influences prognosis and determines tumour grade. We hypothesized that Si-NET grade 2 (G2) tumours, which have a higher Ki-67 than G1 tumours, might benefit less from established treatments for metastatic disease. We conducted a retrospective cohort study of 212 patients with metastatic Si-NET G2 treated in two Swedish hospitals during 20 years (2000–2019). Median cancer-specific survival on first-line somatostatin analogues (SSA) was 77 months. Median progression-free survival (PFS) was 12.4 months when SSA was given as monotherapy and 19 months for all patients receiving first-line SSA. PFS after SSA dose escalation was 6 months in patients with radiological progression. Treatment efficacies of SSA and peptide receptor radionuclide treatment (PRRT) were studied separately in patients with Ki-67 of 3–5%, 5–10% and 10–20%. For SSA, PFS was significantly shorter at higher Ki-67 levels (31, 18 and 10 months, respectively), while there was only a minor difference in PFS for PRRT (29, 25 and 25 months). Median PFS for sequential treatment with interferon-alpha (IFNα), everolimus and chemotherapy was 6, 5 and 9 months. IFNα seemed to be effective in tumours with low somatostatin–receptor expression. In conclusion, established treatments appeared effective in Si-NET G2, despite their higher proliferation index compared to G1 tumours. However, efficacy of SSA but not PRRT was reduced at higher Ki-67 levels. SSA dose escalation provided limited disease stabilization.
- 1 March 2023
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 30 (3)
Open AccessTreatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
Small intestinal neuroendocrine tumours (Si-NET) are often studied as a uniform group. Proliferation index Ki-67 influences prognosis and determines tumour grade. We hypothesized that Si-NET grade 2 (G2) tumours, which have a higher Ki-67 than G1 tumours, might benefit less from established treatments for metastatic disease. We conducted a retrospective cohort study of 212 patients with metastatic Si-NET G2 treated in two Swedish hospitals during 20 years (2000–2019). Median cancer-specific survival on first-line somatostatin analogues (SSA) was 77 months. Median progression-free survival (PFS) was 12.4 months when SSA was given as monotherapy and 19 months for all patients receiving first-line SSA. PFS after SSA dose escalation was 6 months in patients with radiological progression. Treatment efficacies of SSA and peptide receptor radionuclide treatment (PRRT) were studied separately in patients with Ki-67 of 3–5%, 5–10% and 10–20%. For SSA, PFS was significantly shorter at higher Ki-67 levels (31, 18 and 10 months, respectively), while there was only a minor difference in PFS for PRRT (29, 25 and 25 months). Median PFS for sequential treatment with interferon-alpha (IFNα), everolimus and chemotherapy was 6, 5 and 9 months. IFNα seemed to be effective in tumours with low somatostatin–receptor expression. In conclusion, established treatments appeared effective in Si-NET G2, despite their higher proliferation index compared to G1 tumours. However, efficacy of SSA but not PRRT was reduced at higher Ki-67 levels. SSA dose escalation provided limited disease stabilization.
- Open Access
- 24 November 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 12 (11) , 1009-1022
Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
- 24 November 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 12 (11) , 1009-1022
Open AccessReal-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
- Open Access
- 26 November 2020
- Published by Springer Nature in Endocrine
- Vol. 72 (3) , 893-904
Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
Purpose: Small intestinal neuroendocrine tumours (siNETs) with a Ki-67 proliferation index between 3 and 20% belong to WHO grade 2. Response to treatment may be monitored by blood chromogranin A (CgA) and urine 5-hydroxyindoleacetic acid (5HIAA). The aim of this retrospective study was to investigate the prognostic value of baseline CgA and 5HIAA and of the early biochemical response to treatment, and to compare different cut-off values used in the literature.Methods: A retrospective cohort study of 184 patients with siNET Grade 2 treated with somatostatin analogues (SSA), interferon-alpha (IFN) or peptide receptor radionuclide therapy (PRRT).Results: Baseline CgA was a statistically significant prognostic marker for both cancer-specific survival (CSS) and progression-free survival (PFS). A cut-off of 5 × ULN (upper limit of normal) was best discriminative in most cases, but 2 × ULN discriminated better for SSA. Baseline 5HIAA was a prognostic marker for CSS in treatment with IFN and PRRT, but not for single SSA. Early changes of CgA and 5HIAA correlated well with CSS (HR 3.18, 95% CI 1.82–5.56 and HR 1.47, 95% CI 1.16–1.86) and PFS (HR 3.08, 95% CI 1.86–5.10 and HR 1.37, 95% CI 1.11–1.68) for SSA, but not for PRRT.Conclusions: Baseline CgA and to a lesser extent 5HIAA are associated with CSS irrespective of treatment used, and with PFS after PRRT, and 5 × ULN provides best discrimination in many, but not all, cases. Early reductions of CgA and 5HIAA are prognostic for treatment with SSA, but not PRRT.
- 26 November 2020
- Published by Springer Nature in Endocrine
- Vol. 72 (3) , 893-904
Open AccessAssessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
Purpose: Small intestinal neuroendocrine tumours (siNETs) with a Ki-67 proliferation index between 3 and 20% belong to WHO grade 2. Response to treatment may be monitored by blood chromogranin A (CgA) and urine 5-hydroxyindoleacetic acid (5HIAA). The aim of this retrospective study was to investigate the prognostic value of baseline CgA and 5HIAA and of the early biochemical response to treatment, and to compare different cut-off values used in the literature.Methods: A retrospective cohort study of 184 patients with siNET Grade 2 treated with somatostatin analogues (SSA), interferon-alpha (IFN) or peptide receptor radionuclide therapy (PRRT).Results: Baseline CgA was a statistically significant prognostic marker for both cancer-specific survival (CSS) and progression-free survival (PFS). A cut-off of 5 × ULN (upper limit of normal) was best discriminative in most cases, but 2 × ULN discriminated better for SSA. Baseline 5HIAA was a prognostic marker for CSS in treatment with IFN and PRRT, but not for single SSA. Early changes of CgA and 5HIAA correlated well with CSS (HR 3.18, 95% CI 1.82–5.56 and HR 1.47, 95% CI 1.16–1.86) and PFS (HR 3.08, 95% CI 1.86–5.10 and HR 1.37, 95% CI 1.11–1.68) for SSA, but not for PRRT.Conclusions: Baseline CgA and to a lesser extent 5HIAA are associated with CSS irrespective of treatment used, and with PFS after PRRT, and 5 × ULN provides best discrimination in many, but not all, cases. Early reductions of CgA and 5HIAA are prognostic for treatment with SSA, but not PRRT.